Form 4: Oramed Pharmaceuticals Director Arie Mayer Reports Significant RSU Grant, Boosting Direct Ownership

Oramed Pharmaceuticals Inc. Director Arie Mayer reported the acquisition of 36,975 Restricted Stock Units (RSUs) in a recent SEC Form 4 filing, increasing his direct beneficial ownership to 133,109 common shares.

Summary

• Oramed Pharmaceuticals Inc. Director Arie Mayer filed a Form 4, disclosing changes in his beneficial ownership of the company's common stock.
• On June 5, 2025, Mr. Mayer acquired 30,000 Restricted Stock Units (RSUs), which will vest in equal portions of 10,000 on January 1, 2026, January 1, 2027, and January 1, 2028.
• Additionally, on June 5, 2025, Mr. Mayer acquired another 6,975 RSUs, which will vest in equal installments on the grant date (June 5, 2025), July 1, 2025, October 1, 2025, and January 1, 2026.
• Following these transactions, Mr. Mayer's direct beneficial ownership of Oramed Pharmaceuticals common stock increased to 133,109 shares.
• All RSUs convert into the Issuer's Common Stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an insider's acquisition of shares (albeit through compensation), which generally signals confidence in the company's future. The long-term vesting schedule further reinforces this positive outlook.

Positives

• The acquisition of Restricted Stock Units (RSUs) by a director aligns management's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule extending to January 2028 for a portion of the RSUs indicates a long-term commitment from the director to the company's future.

Future Outlook

The future outlook, as indicated by this filing, primarily involves the vesting of the granted Restricted Stock Units (RSUs) to Director Arie Mayer over the next few years, with vesting dates extending through January 2028. This suggests a continued alignment of the director's compensation with the company's long-term performance.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors and executives is a common and standard practice across various industries, including the pharmaceutical and biotechnology sectors. This form of equity compensation is widely used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation by Oramed Pharmaceuticals is consistent with common practices observed in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors.
• Companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Moderna (MRNA) frequently utilize RSU grants as part of their executive and director compensation packages to foster long-term commitment and performance alignment.
• The vesting schedules, extending over several years, are typical for RSU grants, aiming to retain talent and encourage sustained performance, comparable to similar arrangements at companies such as Gilead Sciences (GILD) or Amgen (AMGN).

Stakeholder Impact

• Shareholders may view the RSU grants as a positive sign of management's long-term commitment and alignment with shareholder interests, as the value of the compensation is tied to the company's stock performance.
• Employees may see this as a standard practice for executive compensation, potentially reinforcing confidence in the company's leadership.

Next Steps

• Continued vesting of the 30,000 RSUs on January 1, 2026, January 1, 2027, and January 1, 2028.
• Continued vesting of the 6,975 RSUs on July 1, 2025, October 1, 2025, and January 1, 2026.

Key Dates

Keywords

Oramed Pharmaceuticals, ORMP, Arie Mayer, SEC Form 4, Restricted Stock Units, RSU, Insider Ownership, Beneficial Ownership, Director Compensation, Stock Grant